BioDuro, a leading global contract research, development, and manufacturing organization (CRDMO), today announced that Christopher Conway, CEO of Bio X Cell, has been appointed to BioDuro’s board of directors, effective immediately.
“Supported by our investors at Advent International and the Bridgewest Group, BioDuro continues to strengthen its leadership team to drive accelerated growth and innovation across global operations,” said Dr. Armin Spura, CEO of BioDuro. “We are pleased to welcome Chris to our board. His deep expertise in life sciences and proven leadership in scaling R&D operations will be invaluable as we continue to grow our global footprint and deliver best-in-class solutions to our biotech and pharmaceutical partners.”
Mr. Conway has over 25 years of experience in the life sciences industry, including executive roles at New York-based CDMO Curia (formerly AMRI), where he led the company’s R&D business unit, and with Johnson & Johnson, where he held several commercial roles. In addition to his current position as CEO of Bio X Cell, the world’s leading functional antibody solutions provider specializing in large-scale RUO antibody manufacturing and services, Mr. Conway is a board member of the Drug, Chemical & Associated Technologies Association (DCAT). Earlier, he served on the board at Viyash Life Sciences, an integrated end-to-end pharmaceutical company with a presence across niche formulations, APIs, and advanced intermediates.
Commenting on his appointment, Christopher Conway said: “I’m honored to join the board of BioDuro and collaborate with such a dynamic team. The company’s commitment to scientific excellence and global impact aligns perfectly with my passion for advancing drug discovery and development. I look forward to contributing to its continued success.”